SCHEMBL29546005

SCHEMBL29546005

O=C(O)c1ccc2c(c1)CCCC2=O

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.65
MAOA P21397 5/20 0.61
MAOB P27338 5/20 0.61
PRKCI P41743 1/20 0.61
SRD5A2 P31213 5/20 0.57
SRD5A1 P18405 4/20 0.57
HSD17B1 P14061 1/20 0.54
BAZ2B Q9UIF8 1/20 0.54
GRM5 P41594 1/20 0.51
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
CYP2A6 P11509 1/20 0.48
MAPK14 Q16539 3/20 0.46
TTR P02766 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL356493 1.00 ALDH1A1 (0.65) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL1091562 0.96 ALDH1A1 (0.59) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL29431442 0.89 SRD5A2 (0.66) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL1275273 0.89 SRD5A2 (0.66) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL29545918 0.86 ALDH1A1 (0.65) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL552091 0.86 ALDH1A1 (0.65) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL10193085 0.84 BAZ2B (0.65) ALDH1A1MAOAMAOBPRKCIHSD17B1
SCHEMBL9944562 0.84 MAOA (0.59) ALDH1A1MAOAMAOBPRKCISRD5A2
SCHEMBL30853876 0.84 MAOA (0.59) ALDH1A1MAOAMAOBPRKCIHSD17B1
SCHEMBL10436091 0.84 MAOA (0.59) ALDH1A1MAOAMAOBPRKCIHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613752-A1 POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2025-09-10 EP disclosed
US-20250270224-A1 POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2025-08-28 US disclosed
CN-113660932-B Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same 景凯生物科技股份有限公司 2024-07-12 CN disclosed
WO-2024093956-A1 POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR 山东轩竹医药科技有限公司 2024-05-10 WO disclosed
CN-116669736-A Fused heterocyclyl-substituted cyclohexanediimide derivatives, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-08-29 CN disclosed
CN-114230457-B 2-benzylidene tetralone derivatives, and preparation method and application thereof 中山大学 2023-06-09 CN disclosed
CN-110072864-B TDO2 inhibitors 基因泰克公司 2022-05-27 CN disclosed
CN-114230457-A 2-benzylidene tetralone derivatives and preparation method and application thereof 中山大学 2022-03-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270224-A1 POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR PARP1, PARP11, PARP2 ALDH1A1 1101/4885MAOA 1014/4885MAOB 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.